Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2161 to 2175 of 9127 results

  1. Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests

    In development Reference number: GID-HTG10898 Expected publication date: TBC

    HealthTech guidance
    In development

  2. Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma

    In development Reference number: GID-HTG10175 Expected publication date: TBC

    HealthTech guidance
    In development

  3. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  4. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  5. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development Reference number: GID-TA11554 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Alcohol Use Disorders (update)

    In development Reference number: GID-NG10445 Expected publication date: TBC

    NICE guideline
    In development

  7. Catumaxomab for intraperitoneal treatment of malignant ascites caused by EpCAM-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 31 July 2026.

    Technology appraisal guidance
    In consultation

  8. Bladder cancer: diagnosis and management (update): scoping

    We are listening to your views on this NICE guideline. Comments close 6 August 2026.

    NICE guideline
    In consultation

  9. Post-traumatic stress disorder

    Topic prioritisation

    Quality standard
    Topic prioritisation

  10. Anxiety Disorders

    Topic prioritisation

    Quality standard
    Topic prioritisation

  11. Technologies for diagnosing endometriosis in primary care: early use assessment: draft guidance

    We are listening to your views on this HealthTech guidance. Comments close 27 July 2026.

    In consultation

  12. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]

    In development Reference number: GID-TA11572 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Islatravir–lenacapavir for treating HIV-1 in people with virological suppression on standard HIV-1 treatment [TSID12428]

    Awaiting development Reference number: GID-TA12475 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Iberdomide with dexamethasone and daratumumab for treating relapsed or refractory multiple myeloma after 1 or 2 lines of treatment [TSID12415]

    Awaiting development Reference number: GID-TA12466 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Deucravacitinib for treating systemic lupus erythematosus [TSID12405]

    Awaiting development Reference number: GID-TA12035 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development